Loading...
BB Biotech AG
BION.SW•SIX
HealthcareBiotechnology
$29.20
$0.20(0.69%)
BB Biotech AG (BION.SW) Stock Overview
Explore BB Biotech AG’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
155.94%
↑ 155.94%
Profit Growth
$1.37
↑ 136.74%
EPS Growth
$1.37
↑ 136.60%
Operating Margin
157.21%
↑ 382.01%
ROE
3.24%
↑ 136.74%
Dividend Yield
0.00%
↓ 30.08%
Analyst Recommendations data is not available for BION.SWAnalyst Recommendations details for BION.SW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
CEO
Dr. Daniel Koller Ph.D.
Employees
10
Headquarters
Seestrasse 16, Kusnacht
Founded
2000